[go: up one dir, main page]

CA2819894A1 - Composes antiviraux - Google Patents

Composes antiviraux Download PDF

Info

Publication number
CA2819894A1
CA2819894A1 CA2819894A CA2819894A CA2819894A1 CA 2819894 A1 CA2819894 A1 CA 2819894A1 CA 2819894 A CA2819894 A CA 2819894A CA 2819894 A CA2819894 A CA 2819894A CA 2819894 A1 CA2819894 A1 CA 2819894A1
Authority
CA
Canada
Prior art keywords
optionally substituted
independently
occurrence
heterocycle
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2819894A
Other languages
English (en)
Inventor
Allan C. Krueger
Warren M. Kati
William A. Carroll
John K. Pratt
Douglas K. Hutchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA2819894A1 publication Critical patent/CA2819894A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA2819894A 2010-12-16 2011-12-16 Composes antiviraux Abandoned CA2819894A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42390610P 2010-12-16 2010-12-16
US61/423,906 2010-12-16
PCT/US2011/065501 WO2012083170A1 (fr) 2010-12-16 2011-12-16 Composés antiviraux

Publications (1)

Publication Number Publication Date
CA2819894A1 true CA2819894A1 (fr) 2012-06-21

Family

ID=45464913

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2819894A Abandoned CA2819894A1 (fr) 2010-12-16 2011-12-16 Composes antiviraux

Country Status (6)

Country Link
EP (1) EP2651885A1 (fr)
JP (1) JP5906253B2 (fr)
CN (1) CN103354808B (fr)
CA (1) CA2819894A1 (fr)
MX (1) MX2013006951A (fr)
WO (1) WO2012083170A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
EP2367823A1 (fr) 2008-12-23 2011-09-28 Abbott Laboratories Composés antiviraux
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
EP2651923A4 (fr) * 2010-12-15 2014-06-18 Abbvie Inc Composés anti-viraux
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
CN104610332B (zh) * 2015-02-26 2019-11-08 成都安斯利生物医药有限公司 一种制备四氢呋喃-3-三氟硼酸钾的方法
CN104672261A (zh) * 2015-02-27 2015-06-03 成都安斯利生物医药有限公司 一种制备四氢呋喃-3-硼酸频呐醇酯的方法
CN104592278A (zh) * 2015-02-28 2015-05-06 成都安斯利生物医药有限公司 一种制备四氢吡喃-3-硼酸频呐醇酯的方法
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
US10898504B2 (en) 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
GEP20207149B (en) 2016-03-22 2020-09-10 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
EP3448392A4 (fr) 2016-04-28 2020-01-15 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
EP3519413A1 (fr) 2016-10-03 2019-08-07 Janssen Pharmaceutica NV Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
PE20191359A1 (es) 2017-02-27 2019-10-01 Janssen Pharmaceutica Nv Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5
WO2019101182A1 (fr) 2017-11-24 2019-05-31 Janssen Pharmaceutica Nv Composés de pyrazolopyridinone
MX2020005944A (es) 2017-12-08 2020-08-24 Janssen Pharmaceutica Nv Analogos espirobiciclicos novedosos.
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2004093915A1 (fr) * 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Compositions pharmaceutiques contenant des inhibiteurs de protease virale de l'hepatite c
DK2826770T3 (en) * 2005-06-24 2019-01-07 Biotron Ltd Acylguanidine compounds with antiviral activity
MX2008012053A (es) * 2006-03-21 2008-12-17 Joyant Pharmaceuticals Inc Promotores de apoptosis de molecula pequeña.
BRPI0713025A2 (pt) 2006-06-16 2012-04-17 Syngenta Participations Ag compostos derivados de etenila carboxamida úteis como microbiocidas, método de controle ou prevenção de infestação de plantas úteis por microorganismo fitopatogênicos e composição para controle e prevenção dos referidos microorganismos
AU2009322400A1 (en) * 2008-12-03 2011-06-30 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2010091413A1 (fr) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Dérivés du dibenzimidazole liés
WO2010096462A1 (fr) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Dérivés du diimidazole lié
CA2753382C (fr) * 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hepatite c
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
TW201038559A (en) * 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
PE20110679A1 (es) 2009-06-11 2011-10-20 Abbvie Bahamas Ltd Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
WO2010148006A1 (fr) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
BR112012022311A2 (pt) * 2010-03-04 2016-08-23 Enanta Pharm Inc agentes farmacêuticos de combinação como inibidores da replicação de hcv.

Also Published As

Publication number Publication date
MX2013006951A (es) 2013-10-03
JP5906253B2 (ja) 2016-04-20
EP2651885A1 (fr) 2013-10-23
JP2014504296A (ja) 2014-02-20
CN103354808B (zh) 2016-08-10
WO2012083170A1 (fr) 2012-06-21
CN103354808A (zh) 2013-10-16

Similar Documents

Publication Publication Date Title
CN103354808B (zh) 抗病毒化合物
US9394279B2 (en) Anti-viral compounds
CA2807847C (fr) Composes antiviraux
EP2367824B1 (fr) Dérivés de pyrimidine antiviraux
US8921514B2 (en) Anti-viral compounds
US20120115918A1 (en) Anti-Viral Compounds
DK2692346T3 (en) Antiviral 1-phenyl-2,5-DIBENZIMIDAZOL-5-yl-pyrrolidine derivative
AU2016238925B2 (en) Anti-viral compounds
AU2014203655B2 (en) Anti-viral compounds
HK1159619B (en) Anti-viral derivatives of pyrimidine

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20171218